Literature DB >> 6130066

A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder.

J P Feighner, C H Merideth, G A Hendrickson.   

Abstract

The safety and antianxiety and antidepressive effects of buspirone (average 16.5 mg/day) were compared in a double-blind trial with those of diazepam (15 mg/day). The two drugs were nearly equivalent in relieving symptoms of both anxiety and depression in 100 patients. Scores on the impaired cognition factor of the SCL-56 and confusion factor of the POMS showed significantly greater improvement with buspirone than with diazepam. Side effects, such as sedation and drowsiness, were significantly more frequent and severe with diazepam. Buspirone may be particularly indicated for anxious patients with associated depression.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6130066

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  21 in total

1.  (+/-)-1-(2,5-Dimethoxy-4-ethylthiophenyl)-2-aminopropane (ALEPH-2), a novel putative anxiolytic agent lacking affinity for benzodiazepine sites and serotonin-1A receptors.

Authors:  M Reyes-Parada; C Scorza; V Romero; R Silveira; J H Medina; D Andrus; D E Nichols; B K Cassels
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-11       Impact factor: 3.000

Review 2.  5-HT1A partial agonists. What is their future?

Authors:  D A Glitz; R Pohl
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

3.  Effects of long-term administration of imipramine on reticular-elicited hippocampal rhythmical slow activity.

Authors:  X O Zhu; N McNaughton
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

4.  Preference for diazepam, but not buspirone, in moderate drinkers.

Authors:  S M Evans; R R Griffiths; H de Wit
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

5.  Anticonflict and discriminative stimulus effects in the pigeon of a new methoxy-chroman 5-HT1A agonist, (+)S 20244 and its enantiomers (+)S 20499 and (-)S 20500.

Authors:  J E Barrett; E H Gamble; L Zhang; B Guardiola-Lemaitre
Journal:  Psychopharmacology (Berl)       Date:  1994-09       Impact factor: 4.530

6.  Buspirone: an anxiolytic without sedative effect.

Authors:  W F Seidel; S A Cohen; N G Bliwise; W C Dement
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

7.  Minimal changes with long-term administration of anxiolytics on septal driving of hippocampal rhythmical slow activity.

Authors:  X O Zhu; N McNaughton
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

8.  A Retrospective Chart Review of Buspirone for the Treatment of Anxiety in Psychiatrically Referred Youth with High-Functioning Autism Spectrum Disorder.

Authors:  Tolga Atilla Ceranoglu; Janet Wozniak; Ronna Fried; Maribel Galdo; Barbora Hoskova; Melissa DeLeon Fong; Joseph Biederman; Gagan Joshi
Journal:  J Child Adolesc Psychopharmacol       Date:  2018-11-16       Impact factor: 2.576

9.  The diagnosis and treatment of generalized anxiety disorder.

Authors:  Borwin Bandelow; Reinhard Boerner J; Siegfried Kasper; Michael Linden; Hans-Ulrich Wittchen; Hans-Jürgen Möller
Journal:  Dtsch Arztebl Int       Date:  2013-04-26       Impact factor: 5.594

10.  Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder.

Authors:  R Enkelmann
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.